246 related articles for article (PubMed ID: 8324150)
41. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
Snydman DR; Jacobus NV; McDermott LA
Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
[TBL] [Abstract][Full Text] [Related]
42. Beta-lactam resistance in anaerobic bacteria: a review.
Hedberg M; Nord CE
J Chemother; 1996 Feb; 8(1):3-16. PubMed ID: 8835102
[TBL] [Abstract][Full Text] [Related]
43. Beta-lactamases of type culture strains of the Bacteroides fragilis group and of strains that hydrolyse cefoxitin, latamoxef and imipenem.
Eley A; Greenwood D
J Med Microbiol; 1986 Feb; 21(1):49-57. PubMed ID: 3485198
[TBL] [Abstract][Full Text] [Related]
44. Determination of susceptibility of anaerobic bacteria to beta-lactam antibiotics by a tablet diffusion test.
Jansen JE; Bremmelgaard A
APMIS; 1988 May; 96(5):464-70. PubMed ID: 3259887
[TBL] [Abstract][Full Text] [Related]
45. Effects of beta-lactamase-mediated antimicrobial resistance: the role of beta-lactamase inhibitors.
Maddux MS
Pharmacotherapy; 1991; 11(2 ( Pt 2)):40S-50S. PubMed ID: 2041831
[TBL] [Abstract][Full Text] [Related]
46. Susceptibility of intestinal anaerobes to new beta-lactam antibiotics.
Bansal MB; Chuah SK; Thadepalli H
Chemotherapy; 1984; 30(4):237-43. PubMed ID: 6744975
[TBL] [Abstract][Full Text] [Related]
47. In-vitro activity of four penicillin/beta-lactamase inhibitor combinations against cefoxitin-susceptible and cefoxitin-resistant Bacteroides fragilis isolates.
Barry AL; Fuchs PC
J Antimicrob Chemother; 1991 Feb; 27(2):243-4. PubMed ID: 2055814
[No Abstract] [Full Text] [Related]
48. Multilaboratory evaluation of the in vitro activity of 13 beta-lactam antibiotics against 1474 clinical isolates of aerobic and anaerobic bacteria.
Murray PR; Jones RN; Allen SD; Erwin ME; Fuchs PC; Gerlach EH
Diagn Microbiol Infect Dis; 1993; 16(3):191-203. PubMed ID: 8477573
[TBL] [Abstract][Full Text] [Related]
49. Antimicrobial susceptibility of anaerobic bacteria in Sweden in 1983.
Nord CE; Olsson-Liljequist B
Scand J Infect Dis Suppl; 1984; 43():44-9. PubMed ID: 6100139
[TBL] [Abstract][Full Text] [Related]
50. Mechanisms of resistance in anaerobes and new developments in testing.
Finegold SM
Diagn Microbiol Infect Dis; 1989; 12(4 Suppl):117S-120S. PubMed ID: 2686914
[TBL] [Abstract][Full Text] [Related]
51. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.
Venezia RA; Yocum DM; Robbiano EM; Echols RM
Antimicrob Agents Chemother; 1990 Sep; 34(9):1858-61. PubMed ID: 2178340
[TBL] [Abstract][Full Text] [Related]
52. In vitro activity of amoxycillin/clavulanate and ticarcillin/clavulanate compared with that of other antibiotics against anaerobic bacteria: comparison with the results of the 1987 survey.
Pierard D; De Meyer A; Rosseel P; Van Cauwenbergh M; Struelens MJ; Delmee M; Goossens H; Claeys G; Glupczynski Y; Verbist L; Melin P; Lauwers S
Acta Clin Belg; 1996; 51(2):70-9. PubMed ID: 8693871
[TBL] [Abstract][Full Text] [Related]
53. In-vitro activity of amoxycillin and ticarcillin in combination with clavulanic acid compared with that of new beta-lactam agents against species of the Bacteroides fragilis group.
Bourgault AM; Lamothe F
J Antimicrob Chemother; 1986 May; 17(5):593-603. PubMed ID: 3636324
[TBL] [Abstract][Full Text] [Related]
54. Comparative in vitro beta-lactam activity against aerobic and anaerobic surgical isolates.
Edmiston CE; Krepel CJ; Clausz JC; Condon RE
Diagn Microbiol Infect Dis; 1988 Feb; 9(2):105-13. PubMed ID: 3164263
[TBL] [Abstract][Full Text] [Related]
55. A comparison of susceptibility results of the Bacteroides fragilis group and other anaerobes by traditional MIC results and statistical methods.
Aldridge KE; Johnson WD
J Antimicrob Chemother; 1997 Mar; 39(3):319-24. PubMed ID: 9096180
[TBL] [Abstract][Full Text] [Related]
56. Antibiotic susceptibility of anaerobic bacteria with special reference to Bacteroides fragilis.
Dornbusch K; Nord CE; Olsson-Liljeqvist B
Scand J Infect Dis Suppl; 1979; (19):17-25. PubMed ID: 37593
[TBL] [Abstract][Full Text] [Related]
57. [Susceptibility of strict anaerobic bacteria to antibiotics in France: a multicenter study].
Grollier G; Mory F; Quentin C; Girard-Pipau F; Tigaud S; Sedallian A; Dubreuil L
Pathol Biol (Paris); 1994 May; 42(5):498-504. PubMed ID: 7824321
[TBL] [Abstract][Full Text] [Related]
58. Susceptibility patterns and resistance to imipenem in the Bacteroides fragilis group species in Japan: a 4-year study.
Bandoh K; Ueno K; Watanabe K; Kato N
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S382-6. PubMed ID: 8324152
[TBL] [Abstract][Full Text] [Related]
59. [In vitro activities of sulopenem, a new parenteral penem, against anaerobes].
Watanabe K; Kato N; Tanaka-Bandoh K; Tanaka Y; Kato H; Ueno K
Jpn J Antibiot; 1996 Apr; 49(4):367-76. PubMed ID: 8786627
[TBL] [Abstract][Full Text] [Related]
60. Variation in the susceptibility of Bacteroides fragilis group isolates from six Chicago hospitals.
Hecht DW; Osmolski JR; O'Keefe JP
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S357-60. PubMed ID: 8324147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
